Clinical trials: active, in Norway
Head & Neck Cancer
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Re-irradiation of head and neck cancer due to relaps or new cancer in the same area may be beneficial, but also poses a risk since the area has been given radiation previously.
- Trial name
- PRORADNOR-ReIR (NCT07922967)
- Testing
- Proton radiotherapy
- Where
- 4 sites in Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
CML (Chronic Myelogenous Leukemia)
Vididencel in CML-CP Patients With MRD
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Colorectal Cancer, Colorectal Neoplasms
Tailored Nutrition vs. Exercise Prehabilitation Before Colorectal Cancer Surgery
This study will test whether tailored nutritional support before surgery, alone or combined with a structured exercise program, can help adult patients recover better after surgery for colorectal (bowel) cancer.
- Trial name
- crEATe (NCT07922850)
- Testing
- Tailored Nutritional Counselling, Physiotherapist-Guided Exercise Programme
- Where
- 2 sites in Norway
- Volunteers
- 140 people
- Sponsor
- University Hospital of North Norway
Cancer
Pan Tumor Rollover Study
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
- Trial name
- NCT03899155
- Testing
- Nivolumab, Ipilimumab, Cabozantinib
- Where
- 410 sites in United States, Argentina and 36 more
- Volunteers
- 1,500 people
- Sponsor
- Bristol-Myers Squibb
Ischaemic Heart Disease, Ischemic Heart Disease
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
The purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation
- Trial name
- OCTOBER (NCT03171311)
- Testing
- Angiographic guided PCI, OCT guided PCI
- Where
- 38 sites in Belgium, Denmark and 11 more
- Volunteers
- 1,201 people
- Sponsor
- Aarhus University Hospital Skejby
Acute Myeloid Leukemia
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML)…
- Trial name
- NCT05183035
- Testing
- Fludarabine, Cytarabine, Gemtuzumab Ozogamicin
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 120 people
- Sponsor
- PedAL BCU, LLC
Acute Myeloid Leukemia
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation.
- Trial name
- NCT07223814
- Testing
- Bleximenib, Cytarabine, Daunorubicin or Idarubicin
- Where
- 108 sites in United States, Australia and 11 more
- Volunteers
- 875 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Myelodysplastic Syndrome, Anemia
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
The main aim of this study is to assess how much elritercept reduces the need for RBC (red blood cell) transfusions and improves hemoglobin blood values in addition to how safe elritercept is when compared with epoetin alfa.
- Trial name
- ELRiSE MDS (NCT07422480)
- Testing
- Elritercept, Epoetin Alfa
- Where
- 166 sites in United States, Argentina and 26 more
- Volunteers
- 300 people
- Sponsor
- Takeda
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with…
- Trial name
- NCT06393374
- Testing
- Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
- Where
- 314 sites in United States, Argentina and 29 more
- Volunteers
- 1,530 people
- Sponsor
- Merck Sharp & Dohme LLC
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer
Prostate Cancer
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
- Trial name
- NCT04821622
- Testing
- talazoparib plus enzalutamide
- Where
- 312 sites in United States, Argentina and 25 more
- Volunteers
- 599 people
- Sponsor
- Pfizer
Infertility (IVF Patients)
Pilot Study of Discarded Blastocysts
The goal of this observational study is to determine multiomics patterns related to global embryo quality to help overcome the limitations of conventional embryo quality assessment.
- Trial name
- DECODE (NCT07429097)
- Testing
- Multiomics analysis
- Where
- Norway
- Volunteers
- 150 people
- Sponsor
- Igenomix
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 274 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
Major Depression Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Digital Interventions for Relapse Prevention in Adolescence
Some adolescents experience periods of anxiety and/or depression, and some find that these periods return over time. The purpose of this study is to examine whether digital interventions-where individuals work systematically with…
- Trial name
- DigiTIFF (NCT07346911)
- Testing
- Transdiagnostic app intervention, Transdiagnostic mastery course
- Where
- Norway
- Volunteers
- 495 people
- Sponsor
- University of Oslo
Severe Mental Illness, Inflammation
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections
This observational study aims to identify the underlying neurobiological and environmental mechanisms that influence vulnerability or resilience to mental illness in the context of infection and their contribution to severe…
- Conditions
- Severe Mental Illness, Inflammation, Viral Infections, Mood Disorders
- Trial name
- VIRAL-MI (NCT06945627)
- Testing
- This research doesn't involve any kind of intervention on the study participants
- Where
- 4 sites in Belgium, Israel and 2 more
- Volunteers
- 408,551 people
- Sponsor
- Sara Poletti
Essential Thrombocythemia
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
- Trial name
- EXCALIBUR-ET2 (NCT07623200)
- Testing
- INCA033989, Best Available Treatment
- Where
- 192 sites in United States, Australia and 20 more
- Volunteers
- 426 people
- Sponsor
- Incyte Corporation
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation).
- Trial name
- NCT06963827
- Testing
- Mezagitamab
- Where
- 186 sites in United States, Argentina and 24 more
- Volunteers
- 347 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.